CXCL5

Across TCGA pan-cancer cohorts, CXCL5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CXCL5 data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CXCL5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CXCL5 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and UCEC are the cancer types where CXCL5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.853	0.225	.006	23	view →
LSCC	DFS	Tertile	All	1.000	0.696	.006	14	view →
UCEC	DFS	Median	All	1.000	0.933	.021	10	view →
HNSC	DFS	Median	All	1.000	0.907	.013	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CXCL5–PDAC (OS)

Open the PDAC breakdown →